IMAGE

Figure 2

ID
ZDB-IMAGE-260722-3
Publication
Roussange et al., 2026 - Integrative analysis of drug-gene signatures in human pluripotent stem cells reveals prazosin as a novel SQSTM1 regulator for ALS therapeutics
All Figures
Figures for Roussange et al., 2026
Image
Figure Caption

Figure 2 Rosuvastatin and prazosin regulate PLP1 and SQSTM1 transcripts in fibroblasts from PMD and FTD/ALS patients
(A) Schematic representation of the validation process for drug effects in fibroblasts derived from disease-affected patients.

(B) Graphs show PLP1 transcript expression levels in PMD-fibroblasts, analyzed by RT-qPCR following treatment with varying doses of rosuvastatin, compared to non-affected fibroblasts. Data are presented as mean ± SEM from three independent cultures and experiments (n = 3). Statistical significance was determined using one-way ANOVA with Tukey’s post hoc multiple comparisons test. ∗∗p ≤ 0.01 and ∗∗∗p ≤ 0.001.

(C) Western blotting analysis of PLP1 and ACTB proteins in PLP1 mutated fibroblasts treated with 5, 10, and 20μM of rosuvastatin. Data are shown as mean ± SEM of n = 3 independent cultures and experiments. Statistical significance was determined using one-way ANOVA with Dunnett’s post hoc multiple comparisons test. p ≤ 0.05.

(D) Graphs of SQSTM1 transcript expression in FTD/ALS3 fibroblasts from two patients (SQSTM1 K238del and SQSTM1 E396fs), analyzed by RT-qPCR after 24 h treatment with various doses of prazosin. Data are represented as mean ± SEM from three independent cultures and experiments (n = 3). Statistical significance was determined using one-way ANOVA with Dunnett’s post hoc multiple comparisons test. ∗∗∗p ≤ 0.001.

(E and F) Representative images (E) and quantification (F) of SQSTM1 analyzed by Western blot in wild-type and SQSTM1 K238del mutated fibroblasts treated with 10 μM prazosin for 24 h. Data are presented as mean ± SEM from more than three independent experiments (n > 3). Statistical significance was determined using unpaired Student’s t test with Welch’s correction. ∗∗∗p ≤ 0.001.

(G) Representative immunocytochemistry images showing DAPI staining and SQSTM1 staining in SQSTM1-mutated FTD/ALS fibroblasts (K238del and E396fs). Scale bars, 20 μm.

(H and I) Quantifications of nuclei and SQSTM1 puncta per cell following 24 h treatment with 10 or 20 μM prazosin, determined through automated microscope acquisition and analysis. Data are expressed as mean ± SD from three independent cultures and experiments (n = 3). Statistical significance was determined using one-way ANOVA with Dunnett’s post hoc multiple comparisons test. ∗∗p ≤ 0.01 and ∗∗∗p ≤ 0.001.

(J and K) Representative images (J) and quantification (K) of LC3B analyzed by Western blot in non-mutated and SQSTM1 E396fs mutated fibroblasts treated with 10 μM prazosin for 24 h with and without 400 nM Bafilomycin A1 in the last 4 h. Data are presented as mean ± SEM from more than three independent experiments (n > 3). Statistical significance was determined using two-way ANOVA with Šídák’s post hoc test. p ≤ 0.05 and ∗∗p ≤ 0.01.

Acknowledgments
This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Stem Cell Reports